Swiftmerge Acquisition Corp. (NASDAQ:IVCP) announced this afternoon that it has signed a non-binding letter of intent to combine with commercial-stage biotech company HDL.
The parties’ press release did not include a proposed valuation for the deal, but Swiftmerge currently has about $228 million in trust and about two months left before its June 17 transaction deadline. The SPAC aims to advance the LOI to a definitive agreement later this quarter.
Like the target of today’s other SPAC transaction, HDL has developed and commercialized a medical device to treat sufferers of heart disease.
Its PDS-2 system has been approved to treat homozygous familial hypercholesterolemia, a disorder that renders the body less capable of removing harmful cholesterol and more susceptible to heart attacks at an early age.
The PDS-2 uses patients’ own plasma to create natural lipoproteins that can reduce plaque blockages and lower overall risk levels. HDL believes this same approach could be used to treat other disorders of the heart, kidneys, arteries and even neurodegenerative diseases like Alzheimer’s. But, such applications have not yet been approved, according to its website.
Swiftmerge will continue to engage in due diligence efforts as it works towards signing a definitive agreement, but the SPAC will remain in SPACInsider‘s “Searching” column until that time.
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...